Literature DB >> 18236066

MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma.

Gino Marioni1, Elena Gaio, Luciano Giacomelli, Andy Bertolin, Emiliano D'Alessandro, Roberto Stramare, Elisa Facco, Alberto Staffieri, Stella Blandamura.   

Abstract

MASPIN, a member of serpin superfamily, has multifaceted biological functions and an unique tumour suppressing activity. Experimental evidences showed that MASPIN suppresses tumour growth, angiogenesis, invasion and metastasis. Only a very limited number of studies considered MASPIN expression in the upper aero-digestive tract carcinomas. It was recently found that nuclear localization of MASPIN was significantly associated with lower recurrence rate and longer disease-free interval in laryngeal carcinoma. The present study investigated the biological and prognostic role of MASPIN in relation to its subcellular localization in oral carcinoma. Sub-cellular pattern of distribution of MASPIN, nuclear and cytoplasmic MASPIN expressions were immunohistochemically determined in 56 consecutive cases of oral carcinoma. Statistical analysis found a significant association between pN-stage and recurrence of disease (P=0.032) and a significantly longer disease-free interval in pN0 patients than in pN+ ones (P=0.038). None of the subcellular expressions of MASPIN was significantly correlated with recurrence of disease and disease-free interval in our series of oral carcinomas. Sixty-one percent of pN0 cases was strongly MASPIN-positive in the cytoplasm of primary carcinoma cells, 33% of the pN+ cases was MASPIN-positive in the cytoplasm. Statistical analysis found a significant association between MASPIN cytoplasmic expression and pN-stage (P=0.032). Negative MASPIN immunoreactivity in carcinoma cells cytoplasm may be useful to identify patients at risk of disease disseminating to neck lymph nodes. Further investigations are necessary to understand the biological role of cytoplasmic MASPIN localization in oral carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18236066     DOI: 10.1007/s00405-008-0583-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  6 in total

1.  A prognostic role for Nm23-H1 in laryngeal carcinoma treated with postoperative radiotherapy: an introductory investigation.

Authors:  Marco Lionello; Stella Blandamura; Marco Agostini; Claudia Staffieri; Andrea Lovato; Giulia Tealdo; Niccolò Favaretto; Luciano Giacomelli; Lucio Loreggian; Alberto Staffieri; Gino Marioni
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-03       Impact factor: 2.503

2.  Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans.

Authors:  Antonio Bascones-Martínez; Mercedes López-Durán; Jorge Cano-Sánchez; Lydia Sánchez-Verde; Ana Díez-Rodríguez; Pablo Aguirre-Echebarría; Emilio Alvarez-Fernández; Miguel Angel González-Moles; Jaime Bascones-Ilundain; Lorenzo Lo Muzio; Julián Campo-Trapero
Journal:  Oncol Lett       Date:  2012-03-19       Impact factor: 2.967

3.  Maspin expression in epithelial skin tumours: an immunohistochemical study.

Authors:  Asmaa Gaber Abdou; Alaa Hassan Maraee; Mohamed Abd El-Monaem Shoeib; Amany Mohamed Abo Saida
Journal:  J Cutan Aesthet Surg       Date:  2011-05

4.  The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.

Authors:  Jehn-Chuan Lee; Kun-Chun Chiang; Tsui-Hsia Feng; Yu-Jen Chen; Sung-Ting Chuang; Ke-Hung Tsui; Li-Chuan Chung; Horng-Heng Juang
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

5.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

6.  Salivary analysis of oral cancer biomarkers.

Authors:  T Shpitzer; Y Hamzany; G Bahar; R Feinmesser; D Savulescu; I Borovoi; M Gavish; R M Nagler
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.